Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells $730,944.08 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the firm’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total transaction of $730,944.08. Following the sale, the insider owned 5,089,354 shares in the company, valued at approximately $93,033,391.12. This represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, March 25th, Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75.

KalVista Pharmaceuticals Trading Down 5.0%

KALV stock opened at $18.36 on Tuesday. The company’s 50-day simple moving average is $16.12 and its 200-day simple moving average is $14.47. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.95. The firm has a market cap of $940.40 million, a P/E ratio of -4.65 and a beta of -0.35.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company lifted its stake in shares of KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 818 shares in the last quarter. BNP Paribas Financial Markets grew its stake in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares in the last quarter. Rhumbline Advisers raised its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after acquiring an additional 1,458 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in KalVista Pharmaceuticals by 26.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock valued at $110,000 after acquiring an additional 2,061 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in KalVista Pharmaceuticals by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after purchasing an additional 2,402 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KALV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Stifel Nicolaus boosted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wall Street Zen raised KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $32.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.